Edwards Lifesciences Management

Management criteria checks 2/4

Edwards Lifesciences' CEO is Bernard Zovighian, appointed in May 2023, has a tenure of 1.42 years. total yearly compensation is $12.87M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth R$28.64M. The average tenure of the management team and the board of directors is 5.1 years and 4.4 years respectively.

Key information

Bernard Zovighian

Chief executive officer

US$12.9m

Total compensation

CEO salary percentage	7.6%
CEO tenure	1.4yrs
CEO ownership	0.01%
Management average tenure	5.1yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bernard Zovighian's remuneration changed compared to Edwards Lifesciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$13m	US$973k	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$3m	US$642k	US$2b

Compensation vs Market: Bernard's total compensation ($USD12.87M) is above average for companies of similar size in the BR market ($USD5.97M).

Compensation vs Earnings: Bernard's compensation has increased by more than 20% in the past year.

CEO

Bernard Zovighian (56 yo)

1.4yrs

Tenure

US$12,869,020

Compensation

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bernard Zovighian	CEO & Director	1.4yrs	US$12.87m	0.012% R$ 28.6m
Scott Ullem	Corporate VP & CFO	10.8yrs	US$5.95m	0.045% R$ 109.5m
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	8.7yrs	US$4.29m	0.034% R$ 82.6m
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	1.8yrs	US$5.40m	0.034% R$ 81.6m
Andrew Dahl	Principal Accounting Officer	less than a year	no data	0.00029% R$ 699.7k
Todd Brinton	Corporate VP of Advanced Technology & Chief Scientific Officer	5.7yrs	no data	no data
Mark Wilterding	Vice President of Investor Relations	no data	no data	no data
Arnold Pinkston	Corporate VP & General Counsel	5.1yrs	no data	no data
Dirksen Lehman	Corporate Vice President of Public Affairs	11.3yrs	no data	no data
Christine McCauley	Corporate Vice President of Human Resources	12.2yrs	no data	no data
Gary Sorsher	Senior Vice President of Quality & Regulatory Compliance	1.3yrs	no data	no data
Wayne Markowitz	GM & Senior VP of Surgical Structural Heart	1.2yrs	no data	0.00021% R$ 506.7k

5.1yrs

Average Tenure

58yo

Average Age

Experienced Management: E1WL34's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bernard Zovighian	CEO & Director	1.4yrs	US$12.87m	0.012% R$ 28.6m
Kieran Gallahue	Independent Director	9.7yrs	US$335.06k	0.012% R$ 28.8m
Paul LaViolette	Independent Director	4.3yrs	US$329.97k	0.0013% R$ 3.1m
Steven Loranger	Independent Director	8.6yrs	US$335.06k	0.012% R$ 28.6m
Leslie Heisz	Independent Director	8.3yrs	US$356.42k	0.0045% R$ 10.8m
Nicholas Valeriani	Independent Chairman	9.9yrs	US$347.97k	0.011% R$ 27.6m
Leslie Davis	Independent Director	less than a year	no data	no data
David Feinberg	Director	less than a year	no data	no data
Ramona Sequeira	Independent Director	4.4yrs	US$334.97k	0.0018% R$ 4.4m

4.4yrs

Average Tenure

64yo

Average Age

Experienced Board: E1WL34's board of directors are considered experienced (4.4 years average tenure).

Edwards Lifesciences Management

Management criteria checks 2/4

Key information

Recent management updates

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Recent updates

Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024

Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022

Edwards Lifesciences Corporation Announces Results from CLASP IID

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022

Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022

Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries

Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022

Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement

Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022

Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study

Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff

Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2021

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Lifesciences Corporation to Report Q4, 2020 Results on Jan 27, 2021

Edwards SAPIEN 3 TAVI Receives Expanded Approval in Canada

Edwards Lifesciences Corporation to Report Q3, 2020 Results on Oct 21, 2020

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.

Edwards Lifesciences Corporation to Report Q2, 2020 Results on Jul 23, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age